Literature DB >> 21671137

Potential of amino acid/dipeptide monoester prodrugs of floxuridine in facilitating enhanced delivery of active drug to interior sites of tumors: a two-tier monolayer in vitro study.

Yasuhiro Tsume1, John M Hilfinger, Gordon L Amidon.   

Abstract

PURPOSE: To evaluate the advantages of amino acid/dipeptide monoester prodrugs for cancer treatments by assessing the uptake and cytotoxic effects of floxuridine prodrugs in a secondary cancer cell monolayer following permeation across a primary cancer cell monolayer.
METHODS: The first Capan-2 monolayer was grown on membrane transwell inserts; the second monolayer was grown at the bottom of a plate. The permeation of floxuridine and its prodrugs across the first monolayer and the uptake and cell proliferation assay on secondary layer were sequentially determined.
RESULTS: All floxuridine prodrugs exhibited greater permeation across the first Capan-2 monolayer than the parent drug. The correlation between uptake and growth inhibition in the second monolayer with intact prodrug permeating the first monolayer suggests that permeability and enzymatic stability are essential for sustained action of prodrugs in deeper layers of tumors. The correlation of uptake and growth inhibition were vastly superior for dipeptide prodrugs to those obtained with mono amino acid prodrugs.
CONCLUSIONS: Although a tentative general overall correlation between intact prodrug and uptake or cytotoxic action was obtained, it appears that a mixture of floxuridine prodrugs with varying beneficial characteristics may be more effective in treating tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21671137     DOI: 10.1007/s11095-011-0485-7

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  63 in total

1.  Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.

Authors:  J L Grem; N Harold; J Shapiro; D Q Bi; M G Quinn; S Zentko; B Keith; J M Hamilton; B P Monahan; S Donavan; F Grollman; G Morrison; C H Takimoto
Journal:  J Clin Oncol       Date:  2000-12-01       Impact factor: 44.544

2.  Prolidase, a potential enzyme target for melanoma: design of proline-containing dipeptide-like prodrugs.

Authors:  Sachin Mittal; Xueqin Song; Balvinder S Vig; Christopher P Landowski; Insook Kim; John M Hilfinger; Gordon L Amidon
Journal:  Mol Pharm       Date:  2005 Jan-Feb       Impact factor: 4.939

Review 3.  Determinants of drug delivery and transport to solid tumors.

Authors:  J L Au; S H Jang; J Zheng; C T Chen; S Song; L Hu; M G Wientjes
Journal:  J Control Release       Date:  2001-07-06       Impact factor: 9.776

4.  Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hPepT1 in the human intestinal Caco-2 cell line.

Authors:  C U Nielsen; R Andersen; B Brodin; S Frokjaer; M E Taub; B Steffansen
Journal:  J Control Release       Date:  2001-09-11       Impact factor: 9.776

Review 5.  The multilayered postconfluent cell culture as a model for drug screening.

Authors:  J M Padrón; C L van der Wilt; K Smid; E Smitskamp-Wilms; H H Backus; P E Pizao; G Giaccone; G J Peters
Journal:  Crit Rev Oncol Hematol       Date:  2000 Nov-Dec       Impact factor: 6.312

Review 6.  The use of 3-D cultures for high-throughput screening: the multicellular spheroid model.

Authors:  Leoni A Kunz-Schughart; James P Freyer; Ferdinand Hofstaedter; Reinhard Ebner
Journal:  J Biomol Screen       Date:  2004-06

7.  Effect of interleukins response to ECM-induced acquisition of drug resistance in MCF-7 cells.

Authors:  M Ohbayashi; M Yasuda; I Kawakami; N Kohyama; Y Kobayashi; T Yamamoto
Journal:  Exp Oncol       Date:  2008-12

Review 8.  Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus.

Authors:  D J Purifoy; L M Beauchamp; P de Miranda; P Ertl; S Lacey; G Roberts; S G Rahim; G Darby; T A Krenitsky; K L Powell
Journal:  J Med Virol       Date:  1993       Impact factor: 2.327

Review 9.  Experimental anti-tumor therapy in 3-D: spheroids--old hat or new challenge?

Authors:  Juergen Friedrich; Reinhard Ebner; Leoni A Kunz-Schughart
Journal:  Int J Radiat Biol       Date:  2007 Nov-Dec       Impact factor: 2.694

10.  Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer.

Authors:  Azita Monazzam; Raymond Josephsson; Carl Blomqvist; Jörgen Carlsson; Bengt Långström; Mats Bergström
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more
  5 in total

Review 1.  Amino Acids in the Development of Prodrugs.

Authors:  Nuno Vale; Abigail Ferreira; Joana Matos; Paula Fresco; Maria João Gouveia
Journal:  Molecules       Date:  2018-09-11       Impact factor: 4.411

2.  Selection of suitable prodrug candidates for in vivo studies via in vitro studies; the correlation of prodrug stability in between cell culture homogenates and human tissue homogenates.

Authors:  Yasuhiro Tsume; Gordon L Amidon
Journal:  J Pharm Pharm Sci       Date:  2012       Impact factor: 2.327

3.  The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability.

Authors:  Yasuhiro Tsume; Tuba Incecayir; Xueqin Song; John M Hilfinger; Gordon L Amidon
Journal:  Eur J Pharm Biopharm       Date:  2013-12-19       Impact factor: 5.571

4.  Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine.

Authors:  Yasuhiro Tsume; Adam J Drelich; David E Smith; Gordon L Amidon
Journal:  Molecules       Date:  2017-08-10       Impact factor: 4.411

5.  The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs.

Authors:  Yasuhiro Tsume; Blanca Borras Bermejo; Gordon L Amidon
Journal:  Pharmaceuticals (Basel)       Date:  2014-01-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.